Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 18Uveal Melanoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sarcoma 2Salivary Gland Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Intraocular Lymphoma 2Hodgkin Disease 2Brain Neoplasms 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1

Interventions

Doxorubicin 5pazopanib 4Ifosfamide 3pembrolizumab 2Sunitinib 2Radiotherapy, Conformal 2Radiotherapy 2tremelimumab 1temsirolimus 1sintilimab 1saracatinib 1sapanisertib 1romidepsin 1olaratumab 1liposomal doxorubicin 1indolepropanol phosphate 1eribulin 1durvalumab 1Watchful Waiting 1Surgical Procedures, Operative 1Sorafenib 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiation 1Polymerase Chain Reaction 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Methotrexate 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Histiocytoma, Malignant Fibrous × CTLA-4 Antigen × Clear all
NCT02500797 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
164 enrolled 22 charts
Sarcoma

Bone Neoplasms, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡